{'fraction_non_alphanumeric': 0.021538461538461538, 'fraction_numerical': 0.0, 'mean_word_length': 4.719298245614035, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
High stakes immunology.

The short circulatory lifetime of factor VIII (fVIII) is a major obstacle to optimal management of patients with hemophilia A. However, any attempt to modify fVIII to increase its circulatory lifetime is attended by the risk of increasing its immunogenicity. In this issue of Blood , van Helden et al